CervoMed (NASDAQ:CRVO), Inc. (NASDAQ: CRVO) is a medical technology company dedicated to advancing neurovascular intervention through innovative device solutions. Founded in 2019 and headquartered in Redwood City, California, the company focuses on the development, manufacturing and commercialization of minimally invasive products designed to treat complex cerebrovascular disorders. Its core mission is to improve patient outcomes in stroke, aneurysm and other brain vessel pathologies by delivering devices that enhance procedural safety, efficiency and clinical efficacy.
The company’s product portfolio centers on a family of microcatheters, guidewires and intracranial access systems engineered to navigate tortuous vascular anatomy with precision. CervoMed’s flagship offering—the XACT™ Aneurysm Coil System—utilizes a proprietary coil detachment mechanism that simplifies deployment and offers greater control in challenging anatomies. Complementing the coil platform, the STEALTH™ Microcatheter and FOCUS™ Support Catheter provide interventionalists with enhanced pushability and torque response, enabling faster access to distal vessels during emergency stroke interventions.
CervoMed operates globally, with primary markets in the United States, Europe and key Asia-Pacific regions. The company maintains strategic partnerships with leading academic medical centers and regional distributors to facilitate clinical trials, user training and product launches. Its manufacturing and quality systems are ISO 13485 certified, while several products have achieved CE marking and are pending U.S. Food and Drug Administration 510(k) clearance. CervoMed’s collaborative approach extends to research alliances aimed at expanding the potential applications of its platform technology into chronic cerebral ischemia and hemorrhagic stroke therapies.
Leadership at CervoMed combines deep experience from major medical device firms and academic neurosurgical institutions. Chief Executive Officer Sarah Thompson, Ph.D., brings over 15 years of product development and regulatory expertise, while Chief Medical Officer John Lee, M.D., is a renowned interventional neuroradiologist. The board of directors includes seasoned executives from the fields of vascular access, biomedical engineering and health care investment. Together, the team seeks to position CervoMed as a trusted partner for hospitals and clinicians striving to elevate standards of care in neurovascular intervention.
